Key Takeaways Livmarli continues to be MIRM's top growth engine, with 1H 2025 sales up 79.1% year over year.Mirum raised its 2025 revenue guidance to $490-$510 million, citing strong product momentum.Cholbam and Ctexli sales also rose, adding to Mirum's expanding rare-disease drug portfolio.Mirum Pharmaceuticals’ (MIRM) lead product, Livmarli (maralixibat), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.Livmarli, an orally administered ileal b ...